E
89.19
-0.90 (-1.00%)
| Previous Close | 90.09 |
| Open | 90.11 |
| Volume | 533,461 |
| Avg. Volume (3M) | 3,552,982 |
| Market Cap | 51,409,117,184 |
| Price / Earnings (TTM) | 53.09 |
| Price / Earnings (Forward) | 25.64 |
| Price / Sales | 7.75 |
| Price / Book | 4.71 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2026 |
| Profit Margin | 75.71% |
| Operating Margin (TTM) | 29.01% |
| Diluted EPS (TTM) | 2.42 |
| Quarterly Revenue Growth (YOY) | 6.20% |
| Quarterly Earnings Growth (YOY) | 1.70% |
| Total Debt/Equity (MRQ) | 6.86% |
| Current Ratio (MRQ) | 4.45 |
| Operating Cash Flow (TTM) | 876.20 M |
| Levered Free Cash Flow (TTM) | 1.45 B |
| Return on Assets (TTM) | 8.42% |
| Return on Equity (TTM) | 16.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Edwards Lifesciences Corporatio | Mixed | Bullish |
AIStockmoo Score
1.0
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 4.0 |
| Relative Valuation | -5.0 |
| Financial Health | 5.0 |
| AI Insight | NA |
| Weighted Average | 1.00 |
Select this tab to load the latest available analysis.
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.91% |
| % Held by Institutions | 89.29% |
No data within this time range.
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |